In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of ...
The causative agent of the coronavirus disease 2019 (COVID-19) – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – was first detected in Wuhan, China, in December 2019. To date, the virus ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
Amy Sheng (left) is Head of the CRO Program at Sino Biological US Inc. (PA, USA), and has expertise in cell, molecular biology, immunology and biochemistry. In this interview, Amy discusses the ...
Globally, RSV is responsible for an immense health and economic burden, causing an estimated 33 million new ALRI cases and ...
The recombinant vector vaccines segment accounted for a market share of more than 11% in the global veterinary market in 2016. Recombinant vector vaccines mimic a natural process of infection, but ...
Recombinant antibody production has emerged as a potent and ground-breaking technology in biomedical research. It has completely transformed the way scientists and researchers study illnesses, create ...
Please provide your email address to receive an email when new articles are posted on . According to the CDC, manufacturers expect to deliver 188 million to 200 million doses of influenza vaccine in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results